Annexon Inc. Stock News

Here is how Annexon, Inc. (ANNX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

In the latest trading session, Annexon, Inc. (ANNX) closed at $6.17, marking a -0.96% move from the previous day.

Annexon (ANNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Annexon (ANNX). While the effectiveness of this highly sought-after metric is questionable, the posit

Annexon (ANNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.

BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with

Alignment with FDA reached to have phase 3 ARROW study use Best Corrected Visual Acuity ≥ 15-Letter Loss as the primary endpoint; Significance of this could mean competitive advantage. A sham-contro

BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with cla

Annexon, Inc. (ANNX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi

Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET

ANNX produced mixed results from its GA program. While the primary endpoint was not met, an important functional endpoint saw success. However, the market reaction was drastic, and perhaps too drastic

Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.

Annexon still plans a phase 3 study for therapy ANX007. The first therapy to treat geographic atrophy (GA) was approved by the FDA in February.

Two new Breakout Stocks for Week 21 with better than 10% short-term upside, ETF updates and a Dow 30 Pick. Average cumulative returns for 2023 are +74.8% YTD. Last week we had peak gains in ANNX +16%,